Aug 24 (Reuters) – Eli Lilly said on Monday it has launched its oral pill, Foundayo, in the UK for weight management and type 2 diabetes, making it the first country in Europe where the treatment is available.

Here are some details: 

• The pill, known chemically as orforglipron, will be available via private prescription after Britain’s medicines regulator authorised the drug on August 10, making it the second GLP-1 oral pill to be cleared in the UK after Novo Nordisk’s Wegovy.

• Lilly said it was working with England’s health cost-effectiveness watchdog, the National Institute for Health and Care Excellence (NICE), on a potential roll-out at the state-run National Health Service.

• Lilly said Foundayo will likely be priced between £100 and £120, lower than its Mounjaro injection’s £330 for a month’s supply.

• Foundayo remains under review in the European Union, while Novo’s Wegovy pill has won a positive recommendation from the European Medicines Agency, with a final decision from the European Commission pending.

(Reporting by Raechel Thankam Job in Bengaluru; Editing by Leroy Leo)


Source link

Author

Shin John
Shin JohnYtv Market News
Share-market news writer and analyst with deep experience covering equities, commodities, forex, and cryptocurrencies for readers in the USA, UK, Canada, and Australia. Ytv Market News delivers timely market updates, practical trading insights, and clear explanations of macro and company-level catalysts that move prices. Combines on-the-ground financial reporting with technical analysis, using concise charts and actionable ideas to help investors and traders make smarter decisions.